Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data
- 2 hours ago
- 1 min read
He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.
Coverage brought to you by










.png)
